Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying …
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?
view original post